Jennifer Wilson

Jennifer Wilson

ASSISTANT PROFESSOR
BIOENGINEERING

420 Westwood Plaza 5121 Engineering V, 4121D University of California Los Angeles, CA 90095-1600

Email:

Websites

RESEARCH AND INTERESTS
Dr. Jennifer L. Wilson is an Assistant Professor at the UCLA Department of Bioengineering. With the Lab for the Understanding of Network Effects (LUNE), Dr. Wilson studies how proteins downstream of drug targets affect drug-induced phenotypes – the ability to mitigate disease or cause side effects. The lab aims to develop engineering principles for rationally designing novel drug targets by accounting for downstream protein effects.
 
Our projects span a range of areas, including:
    • Leveraging patient genetic data to understand differential response to therapy
    • Integrating ‘omics measurements to parameterize network edges
    • Developing novel gold standard datasets for benchmarking PPI network discovery
    • Using observational studies to test drug repurposing predictions
    • Developing tissue- and cell-type- specific models to improve prediction performance of drug-induced side effects
    • Data characterization and benchmarking for improved prediction performance
    • Meta-analysis to understand PPI edges common to drugs with similar effects
NOTABLE PUBLICATIONS
  • Wilson, JL, Gravina A, Grimes K. "Full title: From random to predictive: a context-specific interaction framework improves selection of drug protein-protein interactions for unknown drug pathways” (submitted).
  • Wilson, JL, Stepanov N, Wong M, Petkovic D, Altman RB. “PhenClust, a standalone tool for identifying trends within sets of biological phenotypes using semantic similarity and the Unified Medical Language System Metathesaurus”. JAMIA Open (in press).
  • Wilson JL*, Cheung KWK*, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. “Scientific Considerations for Global Drug Development”. Sci Trans Med. 2020; 12 (554). doi: 10.1126/scitranslmed.aax2550
  • Wilson, JL, Lu D, Corr N, Fullerton A, Lu J. “An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias”. PLoS Computational Biology. 2020; 16 (7), e1007620. doi: 10.1371/journal.pcbi.1007620
  • Wilson, JL, Wong M, Chalke A, Stepanov N, Petkovic D, Altman RB. “PathFXweb: a web application for identifying drug safety and efficacy phenotypes.” Bioinformatics. 2019 May 22. pii: btz419. doi: 10.1093/bioinformatics/btz419
  • Wilson, JL “A scientist engineer’s contribution to therapeutic discovery”. Experimental Biology and Medicine. 2018; 0: 1–8. doi: 10.1177/1535370218813974
  • Wilson, JL, Racz R, Liu T, Adeniyi O, Sun J, Ramamoorthy A, Pacanowski M, Altman RB. “PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development”. PLoS Comput Biol. 2018; 14(12): e1006614. doi: 10.1371/journal.pcbi.1006614.
  • Das, A., Merril P, Wilson JL, Freshcorn B, Paige M, Capitosti S, Brown M, Botchwey E. “Evaluating angiogenic potential of small molecules using genetic network approaches" Regenerative Engineering and Translational Medicine. 2018; 1-12. doi: 10.1007/s40883-018-0077-8
  • Wilson JL, Altman RB. “Biomarkers: Delivering on the expectation of molecularly driven, quantitative health”. Exp Biol Med. 2018 Feb;243(3):313–22. doi: 10.1177/1535370217744775
  • Wilson JL, Kefaloyianni E, Stopfer L, Harrison C, Sabbisetti VS, Fraenkel E, et al. “Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding”. Mol Cancer Res. 2018 Jan;16(1):147–61. doi: 10.1158/1541-7786.MCR-17-0140
  • Wilson JL, Dalin S, Gosline S, Hemann M, Fraenkel E, Lauffenburger DA. “Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia”. Integr Biol (Camb). 2016 Jul 11;8(7):761–74. doi: 10.1039/c6ib00040a
  • Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA. “Integrated network analyses for functional genomic studies in cancer”. Semin Cancer Biol. 2013 Aug;23(4):213–8. doi: 10.1016/j.semcancer.2013.06.004
  • Sefcik LS, Wilson JL, Papin JA, Botchwey EA. Harnessing systems biology approaches to engineer functional microvascular networks. Tissue Eng Part B Rev. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2010 Jun;16(3):361–70. doi: 10.1089/ten.TEB.2009.0611
EDUCATION
B.S., Biomedical Engineering, University of Virginia, 2010
Ph.D., Biological Engineering, Massachusetts Institute of Technology, 2016
UCSF-Stanford Center for Excellence in Regulatory Science and Innovation (CERSI) fellow, 2016-2019
SPARK fellow, Stanford University, 2019-2021
AWARDS AND RECOGNITION
  • Sanofi iDEA Award Recipient, 2019, 2020
  • Pre-doctoral poster prize winner, Systems Approaches to Cancer Biology (April 2016)
  • David H. Koch Graduate Fellowship, 2013-2014
  • NSF Engineering Innovation Fellowship Program, 2013
  • Graduate Women of Excellence Award, MIT, 2012
  • NSF Graduate Research Fellow, 2010